12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Amigal migalastat: Phase II started

Amicus began an open-label, U.S. and European Phase II trial to evaluate Amigal plus ERT with Fabrazyme agalsidase beta or Replagal agalsidase alfa in 18 patients. Last year,...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >